(Very) severe acquired aplastic anemia ((v)SAA) and myelodysplastic syndrome (MDS) are rare diseases in childhood. (V)SAA is a bone marrow (BM) failure syndrome characterized by immune-mediated destruction of hematopoietic progenitors. MDS is a malignant clonal stem cell disorder, of which the hypoplastic variant is, in case of absence of a cytogenetic clone, difficult to separate from (v)SAA. Recently, studies provided a molecular signature of autoimmunity in adult (v)SAA, by showing oligoclonality based on the length of the TCR Vb CDR3 region. We investigated retrospectively the frequency and the discriminative value of TCR Vb CDR3 oligoclonality in pediatric (v)SAA and MDS patients. Peripheral blood (PB) and/or BM mononuclear cell samples of pediatric patients with (v)SAA (n ¼ 38), refractory cytopenia (MDS-RC) (n ¼ 28) and 18 controls were analysed via TCR Vb heteroduplex PCR analysis of extracted RNA. A skewed TCR Vb CDR3 repertoire was found in 21/38 (v)SAA and in 17/28 RC patients in contrast to 2/18 in the control group. These data suggest an overlapping group of RC and SAA patients that may share a common immunemediated pathogenesis. Prospective studies are required to establish the clinical value of TCR Vb CDR3 repertoire analysis to predict the clinical response in these patients.
Introduction
(Very) severe aplastic anemia (v)SAA and myelodysplastic syndromes (MDS) are rare acquired bone marrow (BM) failure disorders in childhood. In the last decade, (v)SAA has shown to be associated with autoimmune phenomena. 1, 2 The use of immunosuppressive therapy (IST) has proven to be of great value in both adults and children with SAA. [3] [4] [5] The administration of combinations of antithymocyte globulin, cyclosporine and steroids with or without granulocyte colony-stimulating factor have resulted in an event-free survival of about 70%. 4, [6] [7] [8] Myelodysplastic syndrome is a clonogenic stem cell disorder, which results in a dysregulation of hematopoiesis and dysplasia in one or more cell lines. From studies of the European Working Group of MDS in Childhood (EWOG-MDS), it has become apparent that over 50% of all pediatric MDS are hypoplastic. 9 Refractory cytopenia (RC) is a subtype of childhood MDS characterized by dysplasia in at least two hematopoietic cell lineages, but less than 2% blasts in the peripheral blood (PB), and less than 5% blasts in the BM. 10 In hypocellular cases discriminating RC from SAA, which is mainly based on morphology and histology, is difficult, especially in case of absence of clonal cytogenetic abnormalities. So far no molecular diagnostic tools are available for characterization and discriminating (v)SAA and MDS-RC.
In adult (v)SAA the variability of the CDR3 region of the Vb chain of the T-cell receptor (TCR) has been described as a useful tool to determine an autoimmune patient-specific signature. Moreover, in adult (v)SAA patients the patient-specific oligoclonal pattern has been used to monitor molecular responses.
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This oligoclonality reflects a skewed variability of the CDR3 length of the TCR Vb chains and therefore is referred to as TCR Vb skewing. [11] [12] [13] [14] In this pilot study, we investigated the frequency of TCR Vb skewing and the value of molecular TCR Vb CDR3 repertoire analysis to discriminate childhood (v)SAA from MDS-RC. Moreover, we analysed whether skewing of individual Vb families differed between (v)SAA and MDS-RC. In addition, we evaluated the most informative compartment (PB or BM) to study this oligoclonality.
Materials and methods

Patients
In this retrospective study, pediatric MDS and (v)SAA patients, diagnosed in pediatric oncology centers and who participated in the EWOG-MDS, were included based on availability of material.
Refractory cytopenia was diagnosed according to EWOG-MDS-98 criteria and (v)SAA according to German SAA 1994 group (Table 1) . 4, 10, 15, 16 All BM biopsies were centrally reviewed by the morphology board of EWOG-MDS and the German SAA group.
The control group consisted of pediatric patients with Evans syndrome (n ¼ 2), congenital BM failure syndrome (n ¼ 7), chronic myeloid leukemia (n ¼ 1), idiopathic thrombocytopenic purpura (n ¼ 2), parvo B19 infection (n ¼ 1) and healthy volunteers (n ¼ 5). For this retrospective study, clinical characteristics such as gender, age at diagnosis, morphologic subtype, treatment schedule and response to treatment were collected from the medical records in the local hospitals. Approval from local medical ethical committees and written informed consent according to the Helsinki agreement were obtained.
Methods TCR Vb CDR3 repertoire analysis. Cryopreserved primary BM and/or PB samples had been collected at diagnosis. Mononuclear cells were isolated from PB and BM by FicollHypaque density centrifugation. RNA isolation was performed as described previously. 17, 18 Following RNA isolation and cDNA synthesis, TCRB (Vb-Cb) PCR was applied. 17, 18 Resulting PCR products were subjected to heteroduplex analysis to determine TCR Vb CDR3 heterogeneity. The TCR Vb CDR3 profiles were compared with those of the control patients.
Skewing of the TCR Vb CDR3 repertoire was scored when an oligoclonal pattern in two or more lanes in the heteroduplex gel was found. Skewing in 2-5 lanes was defined as TCR score 1, whereas skewing in more than 5 lanes was defined as TCR score 2. In non-skewed cases polyclonal patterns were seen in all lanes, defined as TCR score 0.
In a proportion of cases, consecutive follow-up samples were available for TCR Vb CDR3 analysis to determine molecular response after IST.
Statistical analysis
Differences in TCR Vb CDR3 repertoire score distribution between (v)SAA patients, MDS patients and healthy controls were calculated by w 2 analysis. The difference between results of TCR Vb CDR3 repertoire scores in PB and BM were compared using Pearson's correlation.
Results and discussion
In this study, a total of 84 cases were included. TCR Vb CDR3 repertoire analysis was performed in 38 (v)SAA patients (n ¼ 17 SAA and n ¼ 21 vSAA patients), 28 RC patients and 18 controls. Of the RC patients, 10/28 had a normal karyotype, in 16/28 cases cytogenetic abnormalities were found and in 2/28 cases the karyotype was unknown. Oligoclonality (TCR scores 1 and 2) was found in 21/38 (55%) of the (v)SAA patients and in 17/28 (61%) of the RC patients (w 2 analysis, P ¼ 0.8). No difference in TCR score was found between the SAA and the vSAA patients (w 2 analysis, P ¼ 0.28), or between RC patients with a normal karyotype versus patients with cytogenetic abnormalities (w 2 analysis, P ¼ 0.07). In two of the control cases, mild skewing (TCR score 1) was found: one was a healthy control and one was diagnosed with congenital BM failure. A significant difference in TCR skewing pattern was found between (v)SAA þ RC patients Table 1 Diagnostic criteria of MDS-RC and 
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At least bilineage morphologic myelodysplasia Platelets o20 Â 10 9 l
Platelets o20 Â 10 9 l
Acquired clonal cytogenetic abnormalitiy in hematopoietic cells
Reticulocytes o20 Â 10 9 l
Blasts: PB p2%, BM p5% o30% of normal cellularity in BM o30% of normal cellularity in BM Abbreviations: AA, aplastic anemia; ANC, absolute neutrophil count; BM, bone marrow; MDS-RC, myelodysplastic syndrome-refractory cytopenia; PB, peripheral blood; (v)SAA, (very) severe aplastic anemia. *Two of the first three criteria and criterion 4 are mandatory. as compared with the controls (w 2 analysis, P ¼ 0.001), but not between RC and (v)SAA patients (w 2 analysis, P ¼ 0.8). Furthermore, no skewing of specific Vb families was found when (v)SAA were compared with RC patients (Figure 1 ).
Our retrospective TCR Vb CDR3 repertoire study shows that 55% of (v)SAA patients had a skewed TCR pattern indicative of autoimmunity, which may reflect the proportion of patients who responded to IST in clinical pediatric (v)SAA studies. So far no studies have been reported on TCR oligoclonality in pediatric MDS. Our results show that in 61% of the RC patients autoimmunity apparently plays a role. This is comparable with findings in adult MDS patients, in which oligoclonality of the TCR Vb CDR3 repertoire has been described in a high percentage of patients.
14,19-21 Moreover, in elderly MDS patients response to IST has been reported, which is indicative that an autoimmune attack may play a role in the pathogenesis of the disease. [22] [23] [24] [25] [26] [27] [28] Recently, EWOG-MDS performed a pilot study in 31 children with hypoplastic RC and normal karyotype in which a response rate of 71% at 6 months after initiation of IST was shown. 29 This underscores our findings that autoimmunity may indeed play a role in subsets of pediatric MDS.
In two cases of pediatric (v)SAA consecutive follow-up, PB samples were available for TCR Vb CDR3 analysis to determine molecular response. In one clinically responding patient, TCR Vb CDR3 repertoire changed from TCR score 2 to 0 at 20 months after IST (cyclosporine, steroids and antithymocyte globulin) (Figure 2) . The second patient, with an initial TCR score of 2, did not respond to IST and did not show a molecular response either. These findings illustrate that, as has been reported in adult patients, TCR Vb CDR3 analysis might be a valuable molecular response tool in children.
Of the 38 (v)SAA patients, 22 received IST. Response data showed a response in 17 patients (8 complete response (CR) and 9 partial response (PR)) and no response in 4 patients. One patient died during treatment. Although the number of patients who received IST in the aplastic anemia patient group is considerable, it was not the intention of this retrospective study to investigate whether TCR Vb CDR3 analysis is predictive for response, as the used IST regimens (dosages, timing and compounds) and the moment of response assessment (4-7 months) were too variable for this analysis. Future prospective studies are necessary to investigate the value of this molecular tool for response measurement in pediatric (v)SAA and MDS-RC patients.
Until now it is unknown which compartment (PB or BM) gives the best information on T-cell oligoclonality in autoimmune-mediated BM failure. In this study, paired samples were available of 25 cases (Table 2 ), which showed a high level of correlation of TCR Vb CDR3 repertoire scores between BM and PB (Pearson's correlation, r 2 ¼ 0.98). Future studies are necessary to investigate which T-cell subtypes are responsible for this autoimmune phenomenon in respectively PB and BM.
In summary, in this retrospective study TCR Vb CDR3 analysis was not discriminative between RC and (v)SAA. It rather seems that there is overlap between (v)SAA and RC patients, which possibly reflects a common pathogenesis. Prospective studies are necessary to investigate whether there is a role for this molecular tool in pediatric MDS to identify a subset of pediatric BM failure/MDS patients that is associated with autoimmunity and therefore could be treated with IST up-front, and whether it can be employed for monitoring molecular response. Table 2 Comparison of TCR Vb CDR3 scores in paired BM and PB samples Abbreviations: BM, bone marrow; PB, peripheral blood; TCR, T-cell receptor. Pearson's r 2 ¼ 0.98. TCR score 0: no skewing: polyclonal pattern in all lanes. TCR score 1: skewing: oligoclonality in 2-5 lanes. TCR score 2: skewing: oligoclonality in more than 5 lanes.
